Table 3 Summary of literature report on pneumothorax in COVID-19 patients. Data are presented to compare clinical and radiographic characteristics and clinical outcomes
From: Pneumothorax in COVID-19 disease- incidence and clinical characteristics
| Â | Age yr/Gender | CT characteristics | Complication | Risk Factors | Time to onset, days | Chest tube | Time to resolution (days) | Outcomes |
|---|---|---|---|---|---|---|---|---|
Zhou et al. [3] | 38/M | Bilateral GGOs and consolidations in the lower lobes | Pneumomediastinum | None | 11 | Â | 14 | Survived |
Wang et al. [5] | 36/F | Bilateral Patchy GGOs and consolidations | Pneumomediastinum | NIV | Day 0–12 days after onset of symptoms |  |  | Died due to ARDS |
Sun et al. [6] | 38/M | Patchy peripheral GGOs. Progression to consolidations and bullae | Mediastinal Emphysema, Giant Bulla, Pneumothorax | NIV | Pneumomediastinum 7 days Bullae 21 days PNX 30 days | None |  |  |
Aiolfi et al. [4] | 56/M 70/M | Bilateral peripheral GGOs | Pneumothorax | Invasive Mechanical Ventilation Preexisting emphysema | 2 and 5 days after intubation | Yes |  | Thoracotomy and bleb resection were performed for persistent pneumothorax |
Liu et al. [11] | 38/M | Bilateral Patchy GGOs and consolidations, progression to cystic formation | Pneumothorax | None | 26 | None | 5 | Survived |
Wang et al. Wang et al. [10] | 62/M | Bilateral areas of GGOs in the peripheral areas | Pneumomediastinum Pneumothorax Subcutaneous emphysema | None | 20 | None | 16 | Survived |